Professor Ranjit Manchanda
Professor of Gynaecological Oncology & Consultant Gynaecological Oncologist; Co-Lead, Cancer Prevention Unit
Email: r.manchanda@qmul.ac.ukRoom Number: Room 131, Wolfson Institute
Profile
I was appointed as Professor of Gynaecological Oncology at Wolfson Institute of Population Health, QMUL in Sep 2019. I worked at Barts Cancer Institute, QMUL as a Clinical Senior Lecturer from June 2015. I have worked as a consultant Gynaecological Oncologist at Barts Health NHS Trust from June 2015. From 2014- 2015 I worked as a Locum Consultant Gynaecological Oncologist at Barts Health and Honorary Senior Lecturer at University College London, UK. I completed a PhD in gynaecological oncology at UCL, followed by a NIHR ACL Fellowship and subspecialty training in gynaecological oncology from UCLH and Bart's Hospital.
Research:
My research is focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and precision medicine approaches for risk prediction, population stratification, targeted screening, cancer prevention (including surgical) and management of familial gynaecological cancer. I have a keen research interest in health economic issues related to these areas.
I am Chief Investigator (CI) on PROTECT (PROTECT: Population based Germline testing for Early detection and Cancer Prevention); PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) trial; DETECT-2 (Direct to Patient testing at Cancer diagnosis for Precision Prevention) study; PROMISE Feasibility study (pilot general population testing and personalised ovarian cancer risk prediction study); SIGNPOST (SystematIc GeNetic testing for Personalised Ovarian cancer Therapy) study and RRESDO (study evaluating attitudes towards early salpingectomy) studies; Co-PI of GCaPPS trial (population based BRCA testing RCT in the Jewish population); Co-Lead for UKCOGS (UK COVID and Gynaecological Cancer Study); Co-lead for SURAKSHA- South Asian Breast Cancer Risk Prediction, Genetic testing & Health Management programme. I have worked on ovarian cancer screening trials (UKCTOCS, UKFOCSS and ALDO).
Research
Publications
- Barrett JE, Jones A, Evans I et al. (2022), The DNA methylome of cervical cells can predict the presence of ovarian cancer $nameOfConference
- Gaba F, Oxley S, Liu X et al. (publicationYear), Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews $nameOfConference
- Sun L, Cui B, Wei X et al. (2022), Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China $nameOfConference
- Taylor A, Sundar SS, Bowen R et al. (2022), British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic $nameOfConference
- Cibula D, Dostálek L, Jarkovsky J et al. (2022), Post-recurrence survival in patients with cervical cancer $nameOfConference
- Gaba F, Goyal S, Marks D et al. (2022), Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: A qualitative study $nameOfConference
- Manchanda R (2022), Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer $nameOfConference
- Taylor JA, Burnell M, Ryan A et al. (2022), Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS $nameOfConference
- Taylor A, Sundar SS, Bowen R et al. (2022), British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic $nameOfConference
- Kriplani D, Olivar AA, Tchrakian N et al. (2022), Concise Reporting of Benign Endometrial Biopsies is an Acceptable Alternative to Descriptive Reporting. $nameOfConference
- Manchanda R, Gaba F, Talaulikar V et al. (2022), Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 $nameOfConference
- Manchanda R (2022), Special Issue “Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer” $nameOfConference
- Lee A, Yang X, Tyrer J et al. (2021), Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. $nameOfConference
- Oonk MHM, Slomovitz B, Baldwin PJW et al. (2021), Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II $nameOfConferenceDOI: 10.1200/JCO.21.00006
- Philpott S, Raikou M, Manchanda R et al. (2021), 423 Results of the avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance program for BRCA mutation-carriers $nameOfConference
- Manchanda R, Oxley S, Ghaem-Maghami S et al. (2021), COVID-19 and the impact on gynecologic cancer care $nameOfConferenceDOI: 10.1002/ijgo.13868
- Cibula D, Dostálek L, Jarkovsky J et al. (2021), The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer $nameOfConference
- Sundar S, Cummins C, Balega J et al. (2021), 718 Investigating impact of ultra-radical surgery in advanced ovarian cancer using population level data linked to the SOCQER 2 multicentre study Ovarian cancer
- Reisel D, Burnell M, Side L et al. (2021), 874 Uptake of population based BRCA-testing across Jewish denominations and affect of cultural and religious factors: a cohort study Prevention of gynaecologic cancer
- Van Lonkhuijzen L, Dostalek L, Jarkovsky J et al. (2021), 942 Survival after recurrence in early-stage cervical cancer patients Cervical cancer
- Cibula D, Jarkovsky J, Van Lonkhuijzen L et al. (2021), 960 The annual recurrence risk model for tailored surveillance strategy in cervical cancer patients Cervical cancer
- Gaba F, Blyuss O, Rodriguez I et al. (2021), 984 Impact of SARS-CoV-2 on training and mental wellbeing of surgical gynaecological oncology trainees Miscellaneous
- Rockall AG, Barwick TD, Wilson W et al. (publicationYear), DIAGNOSTIC ACCURACY OF FEC-PET/CT, FDG-PET/CT AND DIFFUSION-WEIGHTED MRI IN DETECTION OF NODAL METASTASES IN SURGICALLY TREATED ENDOMETRIAL AND CERVICAL CARCINOMA $nameOfConference
- Gaba F, Blyuss O, Rodriguez I et al. (2021), Impact of SARS-CoV-2 on training and mental well-being of surgical gynecological oncology trainees. $nameOfConference
- Chandrasekaran D, Sobocan M, Blyuss O et al. (2021), Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: Signpost study $nameOfConference
- Menon U, Gentry-Maharaj A, Burnell M et al. (2021), Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial $nameOfConference
- Reisel D, Baran C, Manchanda R (publicationYear), Preventive population genomics- the model of BRCA related cancers $nameOfConference
- Mariño IP, Vázquez MA, Blyuss O et al. (2021), Computational learning methods for early detection of ovarian cancer Emerging Topics in Artificial Intelligence (ETAI) 2021DOI: 10.1117/12.2594225
- Menon U, Gentry-Maharaj A, Burnell M et al. (2021), Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial $nameOfConference
- Phadnis S, Selek S, Farrag A et al. (2021), Cytoreduction surgery for recurrent ovarian cancer: cohort study from UK tertiary centre $nameOfConference
- Cohen PA, Powell A, Böhm S et al. (2021), Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448 (Gynecologic Oncology (2019) 154(2) (441–448), (S0090825819311813), (10.1016/j.ygyno.2019.04.679)) $nameOfConference
- Gaba F, Blyuss O, Chandrasekaran D et al. (2021), Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study $nameOfConference
- Sundar S, Manchanda R, Gourley C et al. (2021), British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom. $nameOfConference
- Gaba F, Robbani S, Singh N et al. (2021), Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): Protocol for a prospective non-randomised multi-center trial $nameOfConference
- Reisel D, Burnell M, Side L et al. (2021), Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study $nameOfConference
- Sundar S, Cummins C, Kumar S et al. (2021), Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study $nameOfConference
- Gaba F, Blyuss O, Sanderson S et al. (2020), 401 Population testing and personalised ovarian cancer risk prediction for risk adapted targeted prevention Prevention of gynaecologic cancer
- Gaba F, Blyuss O, Legood R et al. (2020), 505 Attitudes towards risk reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study Prevention of gynaecologic cancer
- Gaba F, Marks D, Saridogan E et al. (2020), 507 Surgical decision making in premenopausal brca carriers considering risk reducing early-salpingectomy or salpingo-oophorectomy: a qualitative study Prevention of gynaecologic cancer
- Gallagher A, Waller J, Manchanda R et al. (2020), Women’s intentions to engage in risk-reducing behaviours after receiving personal ovarian cancer risk information: An experimental survey study $nameOfConference
- Krämer P, Talhouk A, Brett MA et al. (2020), Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma $nameOfConference
- Manchanda R, Lieberman S, Gaba F et al. (2020), Population Screening for Inherited Predisposition to Breast and Ovarian Cancer $nameOfConference
- Evans O, Manchanda R (2020), Population-based genetic testing for precision prevention $nameOfConference
- Manchanda R, Sun L, Patel S et al. (2020), Economic evaluation of population-based brca1/brca2 mutation testing across multiple countries and health systems $nameOfConference
- Gentry-Maharaj A, Blyuss O, Ryan A et al. (2020), Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women $nameOfConference
- Gaba F, Blyuss O, Liu X et al. (2020), Population study of ovarian cancer risk prediction for targeted screening and prevention $nameOfConference
- Cohen PA, Powell A, Böhm S et al. (2020), Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448] (Gynecologic Oncology (2019) 154(2) (441–448), (S0090825819311813), (10.1016/j.ygyno.2019.04.679)) $nameOfConference
- Manchanda R, Buist DSM, Evans DGR (2020), Future Research Suggestions for Multigene Testing in Unselected Populations-Reply $nameOfConference
- Evans O, Gaba F, Manchanda R (2020), Population-based genetic testing for Women's cancer prevention $nameOfConference
- Manchanda R (2020), Advances in the screening and prevention of Women's cancers $nameOfConference
- Casey L, Powell A, Bohm S et al. (2020), Role of Ki67 Proliferation Index and CD8 Tumour-Infitrating Lymphocyte Counts in Predicting Outcome in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC) Showing No/Partial Response to Neoadjuvant Chemotherapy $nameOfConference
- Gaba F, Manchanda R (2020), Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers $nameOfConference
- Manchanda R, Burnell M, Gaba F et al. (2020), Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes $nameOfConference
- Ryan N, Wall J, Crosbie EJ et al. (2019), Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results $nameOfConferenceDOI: 10.1111/his.13925
- Gaba F, Chandrasekaran D, Menon U et al. (2019), EP1229 Preventing ovarian cancer through early excision of tubes and late ovarian removal (PROTECTOR) study ePoster Talks: Ovarian + Endometria
- Gaba F, Liu X, Chandrasekaran D et al. (2019), EP1231 Impact of population genetic testing and ovarian cancer risk stratification on the emotional well-being and health of unselected women in a general population ePoster Talks: Ovarian + Endometria
- Sundar S, Cummins C, Kumar S et al. (2019), EP1269 Quality of life after surgery of varying surgical complexity in advanced ovarian cancer: results from the international, prospective, multicenter cohort SOCQER2 study ePoster
- Daia M, Chandrasekaran D, Lawrence A et al. (2019), EP1332 Follow the yellow brick road – Supra-renal para-aortic lymphadenectomy for metastatic ovarian cancer Cinema Viewing
- Gaba F, Farrag A, Lawrence A et al. (2019), EP1342 Ovarian cancer with metastatic inguinal lymphadenopathy: an abdominal approach to inguinal nodes dissection Cinema Viewing
- Dokmeci A, Abdurrayman M, Drymiotou S et al. (2019), EP507 Has the robot been beneficial to endometrial cancer patients? A prospective quality improvement project at a london gynae-oncology tertiary centre ePoster
- Drymiotou S, Dokmeci A, Chandrasekaran D et al. (2019), EP510 Robotic surgery: does high body mass index (BMI) matter? ePoster
- Manchanda R, Burnell M, Gaba F et al. (2019), Randomised trial of unselected BRCA testing in ashkenazi jews: long term outcomes and factors affecting uptake of testing Best Oral/Late-Breaking Abstracts 4 – Miscellaneous
- Sun L, Brentnall A, Patel S et al. (2019), Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis Oral Communication 4 – Gynaecological Cancer
- Sun L, Brentnall A, Patel S et al. (publicationYear), A Cost-effectiveness Analysis of Multigene Testing for All Patients with Breast Cancer $nameOfConference
- Manchanda R, Sun L, Patel S et al. (2019), 10 Global economic evaluation of population-based BRCA1/BRCA2 mutation testing Plenary sessions
- Sun L, Brentnall A, Patel S et al. (2019), 66 Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis $nameOfConference
- Manchanda R, Burnell M, Gaba F et al. (2019), 81 Attitude towards and factors affecting uptake of population based BRCA testing in ashkenazi jews: a cohort study E-Poster discussions
- Tan A, Rivas C, Yorke S et al. (2019), Variation in the outcome reported by studies of interventions for atypical endometrial hyperplasia: a systematic review (the first step in the development of CRUK-funded Core Outcome Sets) RCOG World Congress 2019
- Tan A, Rivas C, Yorke S et al. (2019), Key patient outcomes on studies managing atypical endometrial hyperplasia and endometrial cancer: two sets of patient workshops and semi-structured interviews (the second step in the development of CRUK-funded Core Outcome Sets) $nameOfConference
- Tan A, Rivas C, Yorke S et al. (2019), Variation in the outcome reported by studies of fertility-sparing interventions for atypical endometrial hyperplasia and early endometrial cancer: a systematic review (the first step in the development of CRUK-funded Core Outcome Sets) $nameOfConference
- Tan A, Rivas C, Yorke S et al. (2019), Variation in the outcome reported by studies of interventions for endometrial cancer: a systematic review (the first step in the development of CRUK-funded Core Outcome Sets) $nameOfConference
- Cohen PA, Powell A, Böhm S et al. (2019), Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data $nameOfConference
- Cohen P, Powell A, Böhm S et al. (2019), Pathological Chemotherapy Response Score Predicts Survival in Patients with Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis of Individual Patient Data $nameOfConference
- Crosbie E, MANCHANDA R, Manchester International Consensus Group (2019), The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome $nameOfConference
- GABA F, Piek J, Menon U et al. (2019), Risk reducing early salpingectomy and delayed oophorectomy as a two staged alternative for primary prevention of ovarian cancer in increased risk women: a commentary $nameOfConference
- MANCHANDA R, GABA F (2019), A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm $nameOfConference
- Koutoukidis D, Beeken R, MANCHANDA R et al. (2019), Diet, physical activity, and health-related outcomes of endometrial cancer survivors in a behavioural lifestyle programme: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised controlled pilot trial $nameOfConference
- MANCHANDA R, Matthew B, GABA F et al. (2019), Attitude towards and factors affecting uptake of population based BRCA testing in the Ashkenazi Jewish population: a cohort study $nameOfConference
- Osman M, Chandrasekaran D, Musa E et al. (2018), Evaluation of the diagnostic hysteroscopy service in gynaecology oncology National Trainees Conference 2018
- MANCHANDA R, GABA F (2018), Population Based Testing for Primary Prevention: A Systematic Review $nameOfConference
- Puntambekar S, MANCHANDA R (2018), Surgical pelvic anatomy in gynecologic oncology. $nameOfConferenceDOI: 10.1002/ijgo.12616
- Manchanda R, Gaba F (2018), Population Based Testing for Primary Prevention: A Systematic Review $nameOfConference
- MANCHANDA R, Legood R (publicationYear), Population based germline testing for primary cancer prevention $nameOfConference
- Jiang J, Phadnis S, Miller R et al. (2018), DISTANT RECURRENCES ARE COMMON FOLLOWING PELVIC EXENTERATION FOR MALIGNANCY OF NON-CERVICAL ORIGIN $nameOfConference
- Jiang J, Phadnis S, Miller R et al. (2018), OUTCOMES OF BOWEL RESECTIONS DURING SURGICAL CYTOREDUCTION OF ADVANCED STAGE OVARIAN CANCER: SHOULD WE BE WORKING TOWARDS REDUCING STOMA RATES? $nameOfConference
- Singh N, Piskorz A, Bosse T et al. (2018), P53 IMMUNOHISTOCHEMISTRY AS A SURROGATE FOR TP53 MUTATIONAL ANALYSIS IN ENDOMETRIAL CANCER BIOPSIES $nameOfConference
- Sundar S, Kumar S, Long J et al. (2018), PATIENT REPORTED OUTCOMES (PRO) AFTER SURGERY IN ADVANCED OVARIAN CANCER - INITIAL RESULTS FROM THE INTERNATIONAL, PROSPECTIVE, MULTICENTER SOCQER 2 STUDY $nameOfConference
- Farrag A, Light M, Sahdev A et al. (2018), SOLITARY RECURRENCE OF SQUAMOUS CELL CARCINOMA OF THE CERVIX IN THE OMENTUM - MANAGEMENT OF AN UNUSUAL PRESENTATION $nameOfConference
- Manchanda R, Blyuss O, Gaba F et al. (2018), Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population $nameOfConference
- Yang X, Leslie G, Gentry-Maharaj A et al. (2018), Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study $nameOfConference
- Vazquez MA, Marino IP, BLYUSS O et al. (2018), A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer $nameOfConference
- BLYUSS O, Burnell M, Ryan A et al. (2018), Comparison of longitudinal CA125 algorithms as a first line screen for ovarian cancer in the general population $nameOfConference
- Manchanda R, Patel S, Gordeev VS et al. (2018), Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women $nameOfConferenceDOI: 10.1093/jnci/djx265
- Chuang L, Berek J, Randall T et al. (2018), Collaborations in gynecologic oncology education and research in low- and middle- income countries: Current status, barriers and opportunities $nameOfConference
- Mariño IP, Vázquez MA, Blyuss O et al. (2018), Diagnosis of ovarian cancer based on longitudinal measurements of multiple biomarkers $nameOfConference
- Crusz SM, Chandrasekaran D, Phadnis S et al. (2018), Outcome of patients undergoing delayed debulking surgery (DDS) in advanced ovarian cancer (OC). $nameOfConference
- Chandrasekaran D, Manchanda R (2018), Germline & somatic genetic testing in ovarian cancer patients. $nameOfConference
- Patel S, Legood R, Evans DG et al. (2018), Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women $nameOfConference
- MANCHANDA R, Menon U (2018), Setting the threshold for surgical prevention in women at increased risk of ovarian cancer $nameOfConference
- Meisel SF, Freeman M, Waller J et al. (2017), Impact of a decision aid about stratified ovarian cancer risk-management on women’s knowledge and intentions: a randomised online experimental survey study $nameOfConference
- Manchanda R, Patel S, Antoniou AC et al. (2017), Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry $nameOfConference
- Manchanda R, Gaba F, Bottla K et al. (2017), PREDICTING RISK OF OVARIAN MALIGNANCY IMPROVED SCREENING AND EARLY DETECTION FEASIBILITY STUDY (PROMISE-FS) $nameOfConference
- Koutoukidis DA, Beeken RJ, Manchanda R et al. (2017), Recruitment, adherence, and retention of endometrial cancer survivors in a behavioural lifestyle programme: The Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised pilot trial $nameOfConference
- Gan C, Chenoy R, Chandrasekaran D et al. (2017), Persistence of fimbrial tissue on the ovarian surface after salpingectomy $nameOfConference
- Rosenthal AN, Fraser LSM, Philpott S et al. (2017), Evidence of Stage Shift in Women Diagnosed with Ovarian Cancer during Phase II of the United Kingdom Familial Ovarian Cancer Screening Study $nameOfConference
- Bansal JK, Goldrick IG, Manchanda R et al. (2017), Rapid-access gynecological oncology clinic outcomes in North London, UK $nameOfConferenceDOI: 10.2147/ca.s127369
- MANCHANDA R, Legood R, Antoniou AC et al. (2017), Changing the Risk Threshold for Surgical Prevention of Ovarian Cancer $nameOfConference
- Rosenthal AN, Fraser LSM, Philpott S et al. (2017), Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. $nameOfConference
- Johnston C, Ng JS, Manchanda R et al. (2017), Variations in gynecologic oncology training in low (LIC) and middle income (MIC) countries (LMICs): Common efforts and challenges $nameOfConference
- Manchanda R (2017), Opportunistic salpingectomy for prevention of ovarian cancer $nameOfConference
- Gan C, Bossart M, Piek J et al. (2017), Robotic and Advanced Laparoscopic Surgical Training in European Gynecological Oncology Trainees. $nameOfConference
- Koutoukidis DA, Beeken RJ, Manchanda R et al. (2017), Erratum: Diet and exercise in uterine cancer survivors (DEUS pilot) - piloting a healthy eating and physical activity program: Study protocol for a randomized controlled trial. [Trials. (2016), 17, (130)], DOI: 10.1186/s13063-016-1260-1 $nameOfConference
- Gaba FM, Manchanda R, Gaba FM et al. (2017), Genetic testing for gynaecological cancer $nameOfConference
- Burnell M, Iyer R, Gentry-Maharaj A et al. (2016), Benchmarking of surgical complications in gynaecological oncology: Prospective multicentre study $nameOfConference
- Pennington M, Gentry-Maharaj A, Karpinskyj C et al. (2016), Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). $nameOfConference
- La Russa M, Biliatis I, Brockbank E et al. (2016), CONSERVATIVE TREATMENT FOR FERTILITY SPARING IN YOUNG WOMEN WITH ENDOMETRIAL CANCER AND ATYPICAL HYPERPLASIA. RESULTS FROM A ON GOING PROSPECTIVE SINGLE CENTRE STUDY 16th biennial International Gynecologic Cancer Society (IGCS) meeting
- Manchanda R, Gordeev V, Antoniou A et al. (2016), Cost-effectiveness of systematic population based screening for BRCA1, BRCA2, RAD51C, RAD51D and BRIP1 gene mutations in unselected general population women 16th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2016)
- Phadnis S, Vali S, Oram D et al. (2016), Enhanced recovery after major gynaecological oncology surgery: Are we meeting the standards? $nameOfConference
- Phadnis S, Lawrence A, Oram D et al. (2016), Morbidity and mortality following major surgery for gynaecological malignancy: A prospective observational study from a cancer centre in London $nameOfConference
- Kumar S, Long J, Rudge G et al. (2016), SOCQER-2 Study: Preliminary analysis of multicentre recruitment after surgery in advanced ovarian cancer 16th biennial International Gynecologic Cancer Society (IGCS) meeting, Lisbon, Portugal
- Phadnis S, Korompelis P, Iamprou C et al. (2016), Surgical and oncological outcome of morbidly obese (BMI > 40) women having laparoscopic surgery for early stage endometrial cancer $nameOfConference
- Manchanda R, Legood R, Antoniou AC et al. (2016), Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingooophorectomy' for ovarian cancer prevention: A cost-effectiveness analysis $nameOfConference
- Manchanda R, Burnell M, Loggenberg K et al. (2016), Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations $nameOfConference
- Chuang LT, Randall TC, Denny L et al. (2016), Sister Society Meeting on Global Education Development and Collaboration: Meeting Report $nameOfConference
- Manchanda R, Cibula D (2016), Ovarian Cancer Screening There May Be Light at the End of the Tunnel? $nameOfConference
- Koutoukidis DA, Beeken RJ, Manchanda R et al. (2016), Diet and exercise in uterine cancer survivors (DEUS pilot) - piloting a healthy eating and physical activity program: Study protocol for a randomized controlled trial $nameOfConference
- MANCHANDA R, Menon U (2016), Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial FOR: There is lack of clarity on a number of key issues $nameOfConference
- Manchanda R, Jacobs I (2016), Genetic screening for gynecological cancer: Where are we heading? $nameOfConferenceDOI: 10.2217/fon.15.278
- Manchanda R, Chandrasekaran D, Saridogan E et al. (2016), Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated into Routine Care or Offered in the Context of a Clinical Trial? $nameOfConference
- Blyuss KB, MANCHANDA R, Kurths J et al. (2016), Systems Medicine of Cancer: Bringing Together Clinical Data and Nonlinear Dynamics of Genetic Networks $nameOfConferenceDOI: 10.1155/2016/7904693
- Dilley J, Manchanda R, Johnson M et al. (2016), Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients $nameOfConference
- Manchanda R, Legood R, Pearce L et al. (2015), Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women $nameOfConference
- Manchanda R, Loggenberg K, Burnell M et al. (2015), A NON-INFERIORITY CLUSTER RANDOMISED TRIAL COMPARING TRADITIONAL FACE-TO-FACE AND DVD-BASED GENETIC COUNSELLING IN SYSTEMATIC POPULATION BASED BRCA1/2 TESTING $nameOfConference
- Chandrasekaran D, Menon U, Evans G et al. (2015), Risk Reducing Salpingectomy and Delayed Oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK $nameOfConference
- Chandrasekaran D, Menon U, Evans G et al. (2015), Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK $nameOfConference
- Iyer R, Gentry-Maharaj A, Nordin A et al. (2015), Predictors of complications in gynaecological oncological surgery: A prospective multicentre study (UKGOSOC - UK gynaecological oncology surgical outcomes and complications) $nameOfConferenceDOI: 10.1038/bjc.2014.630
- Jervis S, Song H, Lee A et al. (2015), A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects $nameOfConference
- Manchanda R, Legood R, Burnell M et al. (2015), Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing $nameOfConferenceDOI: 10.1093/jnci/dju380
- Manchanda R, Loggenberg K, Sanderson S et al. (2015), Population testing for cancer predisposing BRCA1/BRCA2 mutations in the ashkenazi-jewish community: A randomized controlled trial $nameOfConferenceDOI: 10.1093/jnci/dju379
- Piek J, Bossart M, Boor K et al. (2015), The work place educational climate in gynecological oncology fellowships across Europe the impact of accreditation $nameOfConference
- Manchanda R, Legood R, Burnell M et al. (2014), POPULATION-BASED TESTING FOR BRCA MUTATIONS (COMPARED TO FAMILY-HISTORY BASED TESTING) MAY BE COST SAVING IN ASHKENAZI-JEWS: A HEALTH-ECONOMICS DECISION ANALYTICAL MODEL $nameOfConference
- Philpott S, Rizzuto I, Fraser L et al. (2013), DETECTION OF NON-OVARIAN CANCERS ON PHASE 2 OF THE UK FAMILIAL OVARIAN CANCER SCREENING STUDY (UKFOCSS) $nameOfConference
- Rosenthal AN, Fraser L, Philpott S et al. (2013), RESULTS OF INTENSIVE ALGORITHM-BASED SCREENING IN THE UK FAMILIAL OVARIAN CANCER SCREENING STUDY (UK FOCSS PHASE 2) $nameOfConference
- Manchanda R, Halaska MJ, Piek JM et al. (2013), The need for more workshops in laparoscopic surgery and surgical anatomy for european gynaecological oncology trainees: A survey by the european network of young gynaecological oncologists $nameOfConference
- Rosenthal AN, Fraser L, Philpott S et al. (2013), Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2) $nameOfConference
- Rosenthal AN, Fraser L, Philpott S et al. (2013), Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2). $nameOfConference
- Kalsi JK, Manchanda R, Menon U (2013), Screening for gynecological cancers $nameOfConferenceDOI: 10.1586/eog.13.5
- Rosenthal AN, Fraser L, Manchanda R et al. (2013), Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule $nameOfConference
- Manchanda R, Godfrey M, Wong-Taylor LA et al. (2013), The need for accredited training in gynaecological oncology: A report from the european network of young gynaecological oncologists (ENYGO) $nameOfConference
- Manchanda R, Drapkin R, Menon U (2013), There is a need for routine peritoneal cytology at RRSO $nameOfConference
- Manchanda R, Saridogan E, Abdelraheim A et al. (2012), Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS) $nameOfConference
- Fourkala EO, Gentry-Maharaj A, Burnell M et al. (2012), Histological confirmation of breast cancer registration and self-reporting in England and Wales: A cohort study within the UK Collaborative Trial of Ovarian Cancer Screening $nameOfConferenceDOI: 10.1038/bjc.2012.155
- Manchanda R, Silvanto A, Abdelraheim A et al. (2012), Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy $nameOfConference
- Menon U, Kalsi J, Jacobs I et al. (2012), International conference on ovarian cancer screening 29th-30th November 2011, Royal College of Physicians, London $nameOfConference
- Manchanda R, Burnell M, Abdelraheim A et al. (2012), Factors influencing uptake and timing of risk reducing salpingo- oophorectomy in women at risk of familial ovarian cancer: A competing risk time to event analysis $nameOfConference
- Gentry-Maharaj A, Kalsi J, Burnell M et al. (2012), Screening of symptomatic women for ovarian cancer $nameOfConference
- Vaes E, Manchanda R, Autier P et al. (2012), Differential diagnosis of adnexal masses: Sequential use of the risk of malignancy index and HistoScanning, a novel computer-aided diagnostic tool $nameOfConferenceDOI: 10.1002/uog.9079
- Brantnerova R, Manchanda R, Colombo N (2012), The European society of gynaecological oncology: update on objectives and educational and research activities. $nameOfConference
- Manchanda R, Drapkin R, Jacobs I et al. (2012), The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer $nameOfConference
- Gultekin M, Dursun P, Vranes B et al. (2011), Gynecologic oncology training systems in Europe: A report from the European network of young gynaecological oncologists $nameOfConference
- Manchanda R, Abdelraheim A, Johnson M et al. (2011), Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status $nameOfConference
- Vaes E, Manchanda R, Nir R et al. (2011), Mathematical models to discriminate between benign and malignant adnexal masses: Potential diagnostic improvement using ovarian histoscanning $nameOfConference
- Jacobs I, Gentry-Maharaj A, Burnell M et al. (2011), Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: A case-control study within the UKCTOCS cohort $nameOfConference
- Pichert G, Jacobs C, Jacobs I et al. (2010), Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers $nameOfConference
- Vaes E, Manchanda R, Nir R et al. (2009), 1329 A sequential use of the Risk of Malignancy Index and Ovarian HistoScanning for the differential diagnosis of adnexal masses $nameOfConference
- Manchanda R, Rosenthal A, Burnell M et al. (2009), Change in stage distribution observed with annual screening for ovarian cancer in BRCA carriers $nameOfConference
- Manchanda R, Menon U, Michaelson-Cohen R et al. (2009), Hereditary non-polyposis colorectal cancer or Lynch syndrome: The gynaecological perspective $nameOfConference
- Manchanda R, Baldwin P, Crawford R et al. (2009), Is close follow up feasible for high-risk cervical premalignant lesion in developing countries? Author's reply $nameOfConference
- Manchanda R, Baldwin P, Crawford R et al. (2008), Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years $nameOfConference
- Manchanda R, Palep-Singh M, Prentice A (2008), Can uterine artery embolisation affect endometrial perfusion and function $nameOfConference
- Manchanda R, Kriplani A (2005), Giant malignant ovarian tumor: A case report $nameOfConference
- Manchanda R, Sriemevan A (2005), Anaphylactoid syndrome caused by amniotic fluid embolism following manual removal of placenta $nameOfConference
- Manchanda R, Refaie A (2005), Acute pneumoperitoneum following coitus. $nameOfConference
- Manchanda R, Varma R, Anya I et al. (2004), Representation of authors and editors from poor countries [1] (multiple letters) $nameOfConference
- Manchanda R, Varma R (2004), Representation of authors and editors from poor countries: observed publication bias may reflect who is funding research. $nameOfConference
- Kriplani A, Agarwal N, Parul et al. (2003), Bilateral seminomas in a 45X/46XY mosaic with Turner's phenotype: An unusual case of mixed gonadal dysgenesis $nameOfConference
- Kriplani A, Manchanda R, Nath J et al. (2002), A randomized trial of danazol pretreatment prior to endometrial resection $nameOfConference
- Kriplani A, Manchanda R, Monga D et al. (2001), Depot medroxy progesterone acetate: A poor preparatory agent for endometrial resection $nameOfConferenceDOI: 10.1159/000052969
- Kriplani A, Agarwal N, Roy KK et al. (2001), Laparoscopic management of Sertoli-Leydig cell tumors of the ovary: A report of two cases $nameOfConference
- Kriplani A, Manchanda R, Agarwal N et al. (2001), Laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovary syndrome $nameOfConference
Supervision
Xia Wei: Decision Analysis and Economic Modelling for Ovarian Cancer Prevention. Funding: Rosetrees Trust and China Medical Board
Samuel Oxley: Prevention of Endometrial Cancer. Funding: Rosetrees Trust
Jyotsna Pundir: Role of Myo-inositol in Poly Cystic Ovary Syndrome. Funding: Self funded
Dhivya Chandrasekaran: Implementation of unselected germline and somatic genetic testing in epithelial ovarian cancer delivered through a cancer-multidisciplinary pathway. Funding: Barts Charity
Faiza Gaba: Targeted Prevention of Ovarian Cancer. Funding: Rosetrees Trust and Barts Charity